Adial Pharmaceuticals (ADIL) Current Assets (2017 - 2026)
Adial Pharmaceuticals (ADIL) posted Current Assets of $4.8 million for Q1 2026, down 22.29% sequentially from $6.2 million in Q4 2025, and up 649.0% YoY from $641245.0 in Q1 2025.
Adial Pharmaceuticals (ADIL) Current Assets (2017 - 2026) Analysis & Trends
Adial Pharmaceuticals has reported Current Assets for 10 years, with the latest figure at $4.8 million in Q1 2026.
- Quarterly Current Assets rose 649.0% year-over-year to $4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 million (up 649.0% YoY) and the FY2025 annual result came in at $6.2 million, up 52.28% from the prior year.
- Current Assets declined to $4.8 million in Q1 2026 per ADIL's latest filing, from $6.2 million in the prior quarter.
- Over five years, Current Assets peaked at $13.0 million in Q1 2022 and troughed at $245469.0 in Q2 2025.
- A 5-year average of $4.0 million and a median of $3.2 million in 2023 frame the typical range for Current Assets.
- The sharpest annual moves came in 2023 and 2026: Current Assets sank 92.26% in 2023, then surged 649.0% in 2026.
- Over 5 years, Current Assets stood at $4.8 million in 2022, then sank by 33.08% to $3.2 million in 2023, then gained by 26.89% to $4.1 million in 2024, then jumped by 52.28% to $6.2 million in 2025, then slipped by 22.29% to $4.8 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $4.8 million, $6.2 million, and $5.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 1.76 Bn |
| 10 | Adial Pharmaceuticals | 27.27 Mn | 27.27 Mn | - | 28.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.80 Mn |
| Dec 31, 2025 | 6.18 Mn |
| Sep 30, 2025 | 5.01 Mn |
| Jun 30, 2025 | 245,469.00 |
| Mar 31, 2025 | 641,245.00 |
| Dec 31, 2024 | 4.06 Mn |
| Sep 30, 2024 | 1.68 Mn |
| Jun 30, 2024 | 1.37 Mn |
| Mar 31, 2024 | 590,226.00 |
| Dec 31, 2023 | 3.20 Mn |
| Sep 30, 2023 | 524,318.00 |
| Jun 30, 2023 | 2.05 Mn |
| Mar 31, 2023 | 2.96 Mn |
| Dec 31, 2022 | 4.78 Mn |
| Sep 30, 2022 | 6.77 Mn |
| Jun 30, 2022 | 9.94 Mn |
| Mar 31, 2022 | 12.96 Mn |
| Dec 31, 2021 | 6.46 Mn |
| Sep 30, 2021 | 7.99 Mn |
| Jun 30, 2021 | 5.59 Mn |